Contepo (fosfomycin disodium)
New active ingredientPriority review
- Region
- 🇺🇸 US
- Active substance
- fosfomycin disodium
- Company
- Meitheal
- Status
- Approved
- FDA approval
- Wed 22 Oct 2025
- Designations
- New active ingredient, Priority review
- Application
- NDA212271
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Wed 22 Oct 2025🇺🇸 FDA approval
FDA approves Contepo (fosfomycin disodium): new active ingredient
Meitheal; NDA212271; New active ingredient, Priority review; powder · source
Follow Contepo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.